Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 8/20 | 0.51 |
| ▸ | MAOA | P21397 | 6/20 | 0.49 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.48 |
| ▸ | MMP2 | P08253 | 1/20 | 0.46 |
| ▸ | MMP13 | P45452 | 1/20 | 0.46 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | DRD1 | P21728 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | HTR7 | P34969 | 1/20 | 0.43 |
| ▸ | HTR6 | P50406 | 1/20 | 0.43 |
| ▸ | ADAM17 | P78536 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | NSD2 | O96028 | 1/20 | 0.42 |
| ▸ | ABL1 | P00519 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9893543 | 0.86 | MAOB (0.47) | MAOBMAOACREBBPMMP2MMP13 | |
| SCHEMBL9893463 | 0.86 | MAOB (0.49) | MAOBMAOACREBBPMMP2MMP13 | |
| SCHEMBL9893250 | 0.83 | MAOB (0.47) | MAOBMAOACREBBPMMP2MMP13 | |
| SCHEMBL28250868 | 0.80 | POLB (0.48) | MAOBMAOAMMP2MMP13TP53 | |
| SCHEMBL4718093 | 0.80 | MAOB (0.75) | MAOBMAOACREBBPMMP2MMP13 | |
| SCHEMBL9893281 | 0.79 | CREBBP (0.57) | MAOBMAOACREBBPMEN1KMT2A | |
| SCHEMBL9893431 | 0.78 | KCNA5 (0.58) | — | |
| SCHEMBL9893537 | 0.76 | BRD4 (0.45) | MAOBCREBBPMMP2MMP13HTR1A | |
| SCHEMBL9893251 | 0.75 | KCNA5 (0.51) | — | |
| SCHEMBL9893492 | 0.74 | KCNA5 (0.47) | MAOBMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8940889-B2 | Process for producing benzo [b] [1,4] diazepine-2,4-dione compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-01-27 | — | — | US | disclosed |
| US-8796447-B2 | Process for producing benzo[B][1,4]diazepine-2,4-dione compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-08-05 | — | — | US | disclosed |
| US-20140194621-A1 | PROCESS FOR PRODUCING BENZO [B] [1,4] DIAZEPINE-2, 4-DIONE COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-07-10 | — | — | US | disclosed |
| EP-2468733-A1 | PROCESS FOR PRODUCING BENZO[B][1,4]DIAZEPINE-2,4-DIONE COMPOUND | Otsuka Pharmaceutical Co., Ltd. (JP) | 2012-06-27 | — | — | EP | disclosed |
| US-20120149899-A1 | PROCESS FOR PRODUCING BENZO[B][1,4]DIAZEPINE-2,4-DIONE COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149899-A1 | PROCESS FOR PRODUCING BENZO[B][1,4]DIAZEPINE-2,4-DIONE COMPOUND | KCNH1, KCNB2, KCNJ2 | MAOB 287/4885MAOA 660/4885CREBBP 1804/4885 |
| US-20140194621-A1 | PROCESS FOR PRODUCING BENZO [B] [1,4] DIAZEPINE-2, 4-DIONE COMPOUND | KCNH1, KCNB2, KCNB1 | MAOB 252/4885MAOA 727/4885CREBBP 1388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.